Favorable outcome of gemcitabine-induced respiratory distress syndrome.
Gemcitabine, a deoxycytidine analog, is used to treat solid tumors, like non-small-cell lung carcinoma. The most commonly reported adverse effects are reversible and generally not fatal. However, among the five cases of acute respiratory distress syndrome (ARDS) secondary to gemcitabine treatment reported since 1997, four were fatal despite corticosteroid therapy. We describe here a patient who received gemcitabine for bronchial epidermoid carcinoma and developed ARDS which spontaneously regressed after gemcitabine withdrawal.
Service de Médecine Interne, Université Paris-Nord, Hôpital Avicenne, 125, route de Stalingrad, 93009 Bobigny Cedex, France.
T
T
Girard
L
L
Mouthon
C
C
Boaziz
M H
MH
Andre
L
L
Guillevin
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D011379:Prognosis; D012128:Respiratory Distress Syndrome / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D013256:Steroids; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
D000893:Anti-Inflammatory Agents; D000964:Antimetabolites, Antineoplastic; D013256:Steroids; D003841:Deoxycytidine; D000093542:Gemcitabine